Valuation Opus Genetics, Inc.

Stocks

Real-time Estimate Cboe BZX 18:02:18 27/10/2026 +04			5-day change	1st Jan Change
3.305 ^USD	-0.45%		-16.46%	+66.67%

10-22	Opus Genetics, Inc. Announces Transition of Ashwath Jayagopal from Chief Scientific and Development Officer, Effective October 19, 2026	CI
10-21	Opus Genetics Wins FDA Clearance for Childhood Blindness Gene Therapy	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	64.53	73.45	68.14	37.57	138.6	276.2	-	-
Change	-	13.82%	-7.23%	-44.87%	268.99%	99.26%	-	-
Enterprise Value (EV)	64.53	73.45	68.14	37.57	138.6	276.2	276.2	276.2
Change	-	13.82%	-7.23%	-44.87%	268.99%	99.26%	0%	0%
P/E	-0.98x	4.06x	-6.54x	-0.55x	-2.51x	-3.39x	-4.68x	-9.7x
PBR	-	-	-	-	-	-	-	-
PEG	-	-0x	0x	-0x	0x	-0.2x	0.2x	0.2x
Capitalization / Revenue	110x	1.84x	3.58x	3.42x	9.76x	20.1x	20.3x	6.09x
EV / Revenue	0x	0x	0x	0x	0x	20.1x	20.3x	6.09x
EV / EBITDA	-	-	-	-	-	-	-	-
EV / EBIT	-0x	0x	-0x	-0x	-0x	-4.92x	-4.15x	-5.34x
EV / FCF	-0x	-	-0x	-0x	-0x	-5.44x	-4.73x	-48.2x
FCF Yield	-30%	-	-1.63%	-68.1%	-25.4%	-18.4%	-21.1%	-2.07%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	-3.82	0.87	-0.46	-2.15	-0.8	-0.9783	-0.71	-0.3423
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	0.589	39.85	19.05	10.99	14.2	13.75	13.62	45.37
EBITDA	-20.79	-	-	-	-	-	-	-
EBIT ¹	-22.7	18.23	-10.56	-62.07	-38.6	-56.08	-66.51	-51.72
Net income ¹	-56.69	17.89	-9.986	-57.53	-49.59	-91.21	-69.08	-46.17
Net Debt	-	-	-	-	-	-	-	-
Reference price ²	3.730	3.530	3.010	1.190	2.010	3.320	3.320	3.320
Nbr of stocks (in thousands)	17,300	20,807	22,638	31,568	68,964	83,196	-	-
Announcement Date	24/03/22	30/03/23	08/03/24	31/03/25	10/03/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
OPUS GENETICS, INC.	-3.39x	-	-	-	276M
ELI LILLY AND COMPANY	37.58x	13.15x	27.92x	0.53%	1,140B
JOHNSON & JOHNSON	38.98x	6.55x	18.43x	2%	641B
ABBVIE INC.	37.5x	8.41x	17.39x	2.4%	507B
ROCHE HOLDING AG	21.33x	5.19x	12.91x	2.53%	383B
MERCK & CO., INC.	102.5x	5.75x	24.67x	2.42%	347B
NOVARTIS AG	21.61x	5.64x	13.85x	2.84%	293B
ASTRAZENECA PLC	22.44x	4.53x	12.94x	1.95%	266B
AMGEN INC.	28.21x	7.23x	12.94x	2.27%	240B
GILEAD SCIENCES, INC.	-46.25x	7.08x	27.47x	2.08%	197B
Average	26.05x	7.06x	18.73x	2.11%	401.41B
Weighted average by Cap.	35.01x	8.33x	20.42x	1.8%